T3D Therapeutics

T3D Therapeutics, founded in Durham, United States, is dedicated to developing innovative treatments for Alzheimer's disease. The company's core mission is to advance its lead drug candidate, T3D-959, which aims to be a 'First-in-Class' and 'Best-in-Class' disease-modifying therapy. T3D-959 is designed to potentially slow, stop, or reverse the progression of Alzheimer's, offering a transformative approach to neurodegenerative disease treatment. The company focuses on leveraging metabolic approaches to address the underlying causes of Alzheimer's.

Notable figures associated with T3D Therapeutics include a distinguished management team and a scientific advisory board comprising experts in neurodegenerative diseases. The company has garnered attention for its promising pipeline and has achieved significant milestones in preclinical and clinical trials. T3D Therapeutics' impact lies in its potential to revolutionize Alzheimer's treatment, providing hope for millions affected by the disease and contributing to the broader field of neurodegenerative research.